Announcements
- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex to Present at the Bio-Europe Spring 2024 Conference
- Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Addex to Present at the Swiss Equities Baader Conference
- Addex to Present at Biotech Showcase™ 2024
More ▼
Key statistics
As of last trade, Addex Therapeutics Ltd (APE1:FRA) traded at 7.65, 70.00% above the 52 week low of 4.50 set on Feb 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.35 |
---|---|
High | 7.65 |
Low | 7.35 |
Bid | 7.65 |
Offer | 8.60 |
Previous close | 7.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.54m |
Free float | 501.90k |
P/E (TTM) | -- |
Market cap | 13.76m USD |
EPS (TTM) | -208.93 USD |
Data delayed at least 15 minutes, as of May 23 2024 14:29 BST.
More ▼